NCT05934513View on ClinicalTrials.gov

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Interventions
DRUG

GFH009

patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guanzhou

All Listed Sponsors
lead

Genfleet Therapeutics (Shanghai) Inc.

INDUSTRY